fls.txt
We evaluate the profitability of each tax-paying component on a historic cumulative basis and a forward-looking basis while performing this analysis.


item1.txt
This benefit for the three and six months ended March 31, 2018 was partially offset by the tax provisions related to foreign income.
 12.
 Cash equivalents of less than $0.1 million and $50.6 million, respectively, at March 31, 2019 and September 30, 2018 consist of money market funds and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets.
The securities in an unrealized loss position as of September 30, 2018 were not considered other-than-temporarily impaired and, as such, the Company did not recognize impairment losses during the period then ended.
The Company used the proceeds of the incremental loan described in Note 8, “Debt” to pay a portion of the purchase price.
The Company maintains an allowance for doubtful accounts representing its best estimate of probable credit losses related to its existing accounts receivable and their net realizable value.
The Company’s warranty obligation is affected by product failure rates, utilization levels, material usage, service delivery costs incurred in correcting a product failure and supplier warranties on parts delivered to the Company.
The fair value was determined based on observable market inputs and classified within Level 2 of the fair value hierarchy due to a lack of an active market for this term loan or a similar loan instrument.
The Company recorded $0.2 million and $0.4 million, respectively of amortization expense related to deferred commissions for the three and six months ended March 31, 2019.
 On April 20, 2018, the Company acquired BioSpeciMan Corporation (“BioSpeciMan”), a Canadian provider of storage services for biological sample materials.
three and six months ended March 31, 2018, the net loss included recurring charges of $1.0 million and $2.1 million, respectively, related to amortization expense of acquired intangible assets.
During the six months ended March 31, 2018, revenue and net loss from 4titude recognized in the Company’s results of operations were $7.8 million and $1.2 million, respectively.
The Company was in compliance with the line of credit covenants as of March 31, 2019 and September 30, 2018.
 10.
Contract assets are classified as current.
The standard requires certain costs incurred to obtain a contract to be recorded as an asset when incurred and expensed as the transfer of control of the underlying performance obligations occur or over the estimated customer life, depending on the nature of the underlying contract.
No triggering events indicating goodwill impairment occurred during the six months ended March 31, 2019.
Contract assets and liabilities are reported on a net basis at the contract level, depending on the contracts position at the end of each reporting period.


item2.txt
Loss from continuing operations was $2.8 million for the second quarter of fiscal year 2019, which includes a $9.1 million loss on extinguishment of debt.
The loan principal amount may be increased by an aggregate amount equal to $75.0 million plus any voluntary repayments of the term loans plus any additional amount such that the secured leverage ratio of the Company is less than 3.00 to 1.00.
This transaction has added a new and innovative platform which we expect to leverage, along with our core capabilities, to add even more value to samples under our care.
The increase in interest expense is due to interest on the $350.0 million incremental term loan secured in the first quarter of fiscal year 2019 used to pay a portion of the purchase price for our acquisition of GENEWIZ.
In October 2017, we acquired all of the outstanding capital stock of 4titude Limited, or 4titude, a U.K.-based manufacturer of scientific consumables for biological sample materials used in a variety of genomic and DNA analytical applications.
We reported revenue of $377.8 million for the six months ended March 31, 2019, compared to $299.6 million for the corresponding period of the prior fiscal year, an increase of $78.2 million, or 26%.
Loss from continuing operations was $2.8 million for the second quarter of fiscal year 2019, which includes a $9.1 million loss on extinguishment of debt.
 Our Brooks Life Sciences segment reported revenue of $85.5 million for the three months ended March 31, 2019 compared to $48.5 million for the corresponding period of the prior fiscal year.
The tax benefit for three months was driven by U.S. losses during the period and includes $0.4 million of stock compensation windfalls.


item3.txt
 Our term loans bear variable interest rates which subject us to interest rate risk.


item4.txt



part2.txt



